Earnings summaries and quarterly performance for Eton Pharmaceuticals.
Executive leadership at Eton Pharmaceuticals.
Board of directors at Eton Pharmaceuticals.
Research analysts who have asked questions during Eton Pharmaceuticals earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for ETON
Also covers: AVDL, BFLY, BVS +17 more
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
2 questions for ETON
Also covers: ABSI, BSEM, CGEN +24 more
ME
Madison Elsaadi
B. Riley Securities
1 question for ETON
Also covers: ARWR
MW
Madison Wynne El-Saadi
B. Riley Securities
1 question for ETON
Also covers: AGEN, CAPR, VTGN +1 more
Recent press releases and 8-K filings for ETON.
Eton Pharmaceuticals Reports Record Q3 2025 Revenue and Strong Product Growth
ETON
Earnings
Revenue Acceleration/Inflection
Product Launch
- Eton Pharmaceuticals reported record third quarter 2025 product revenue of $22.5 million, an increase of 129% year-over-year and 19% sequentially, marking its 19th consecutive quarter of sequential product revenue growth. The company generated $12 million in cash from operations and achieved adjusted EBITDA of $2.9 million.
- Growth was driven by Alkindi Sprinkle, Increlex, and Galzin, with Galzin exceeding its year-end 2025 target by reaching over 200 active patients. The FDA accepted the ET-600 NDA submission for review, assigning a PDUFA date of February 25th, with a commercial launch anticipated shortly after.
- Adjusted gross margin for Q3 2025 was 45%, impacted by non-recurring ex-U.S. Increlex transition costs, but is projected to be approximately 70% in Q4 2025 and north of 75% by 2028. The company is also in late-stage discussions for two additional ultra-rare disease product acquisitions.
Nov 6, 2025, 9:30 PM
Eton Pharmaceuticals Reports Strong Q3 2025 Financial Results and Pipeline Progress
ETON
Earnings
Product Launch
Revenue Acceleration/Inflection
- Eton Pharmaceuticals reported Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and its 19th consecutive quarter of sequential product sales growth.
- For Q3 2025, the company achieved non-GAAP fully diluted EPS of $0.04 and Adjusted EBITDA of $2.9 million, with basic and fully diluted GAAP EPS at $(0.07).
- The company generated $12.0 million of cash from operations during the quarter.
- The New Drug Application (NDA) for ET-600 was accepted for review by the FDA, with a PDUFA date assigned for February 25, 2026.
- INCRELEX was the largest revenue contributor in Q3 2025, and the GALZIN® launch is ahead of plan, exceeding its previous year-end target of 200 active patients.
Nov 6, 2025, 9:25 PM
Eton Pharmaceuticals Reports Strong Q3 2025 Financial Results and Pipeline Progress
ETON
Earnings
Revenue Acceleration/Inflection
Product Launch
- Eton Pharmaceuticals reported Q3 2025 product sales of $22.5 million, representing its 19th consecutive quarter of sequential product sales growth and a 129% increase over Q3 2024.
- The company generated $12.0 million of cash from operations in Q3 2025, contributing to $37.1 million in cash and cash equivalents as of September 30, 2025.
- For Q3 2025, GAAP basic and fully diluted EPS was $(0.07), non-GAAP fully diluted EPS was $0.04, and Adjusted EBITDA was $2.9 million.
- The New Drug Application (NDA) for ET-600 was accepted for review by the FDA, with a PDUFA date of February 25, 2026, and a potential launch anticipated in Q1 2026.
- Management expects Q4 2025 adjusted gross margin of approximately 70% and projects Adjusted G&A expenses to remain flat or decline in the same period.
Nov 6, 2025, 9:05 PM
Quarterly earnings call transcripts for Eton Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more